MS and Demyelinating Disorders

The agency is anticipating upward of 200 INDs per year by 2020 and between 10 and 20 cell and gene therapy approvals per year by 2025.

The Group Medical Director for Neuroscience at Genentech discussed the ORATORIO trial findings, as well as what the upcoming ORATORIO-HAND trial will evaluate.

The AAN position statement author further addressed the opposing position of the Nevada law, the AAN’s position on brain death, and what clinicians need to know in regard to determining it.

The principal medical science director at Genentech spoke about the decisions behind the tools being used for measurement, and what the neurologists can get from the data.

Neurology News Network for the week of January 12, 2019.

The Chair of the AAN’s Ethics, Law and Humanities Committee spoke to the American Academy of Neurology’s goal to improve the consistency of determining brain death.

Previous analysis has suggested that an extended dosing regimen can reduce the risk of progressive multifocal leukoencephalopathy for patients with relapsing multiple sclerosis.

Final approval is expected by June 20, 2020, ahead of the generic erosion following the patent expiration of Biogen’s Tecfidera.

The anti-CD20 antibody showed greater reductions in Expanded Disability Status Scale scores over a decade in patients with SPMS compared to matching controls never treated with it.

This guide includes everything you need to know about fingolimod (Gilenya, Novartis) for the treatment of relapsing multiple sclerosis in adults and children.

The Clinical Director of the NHGRI spoke about the impact of the NIH program and its future development.

The position statement’s author noted that a lack of specificity in laws and inconsistencies in protocols has led to confusion surrounding brain death in several high-profile cases.

The program’s director spoke about its genesis and evolution into a more widespread initiative which has helped improve next-generation genome sequencing.

Neurology News Network for the week of December 22, 2018.

With more than a dozen disease-modifying therapies, some have set their sights on developing an agent designed to promote remyelination.

The chief of the Multiple Sclerosis Division at the Perelman School of Medicine explained how an increase in the number of MS neurologists could improve the state of care.

The trial of the mesenchymal stem cells therapy is expected to commence in early 2019.

Bayer’s pharmacovigilance database showed a similar rate of birth defects and spontaneous abortions in those exposed to IFN-β in comparison with available general population worldwide estimates.

The professor of neurology at the Hospital of the University of Pennsylvania and the chief of the Multiple Sclerosis Division at the Perelman School of Medicine spoke about this strategy and why it came to be.

This brief year-end slideshow highlights significant progress in research into migraine, Alzheimer disease, stroke, multiple sclerosis, and autism.

If approved, diroximel fumarate may offer a differentiated gastrointestinal tolerability profile for patients with relapsing forms of multiple sclerosis.

Based on the findings, patients who are stable on their current IFN-ß therapy should remain on that therapy, but further studies are needed on when to switch therapies in multiple sclerosis.

Although the trial was small, the findings reiterate what has previously been shown with natalizumab in larger, prior studies.

Physicians have debated whether or not cognition is a reliable marker for disease deterioration, and if it should necessitate a change in therapy.

The trial results indicate that EBV-specific adoptive T cell therapy is well tolerated and further back this approach in efficacy trials.